PHC Holdings buys Thermo Fisher’s anatomical pathology division
Category: #health  By Pankaj Singh  Date: 2019-07-01
  • share
  • Twitter
  • Facebook
  • LinkedIn

PHC Holdings buys Thermo Fisher’s anatomical pathology division

PHC Holdings Corporation, a global innovator in healthcare solutions, has reportedly concluded its acquisition of Thermo Fisher Scientific Inc.’s Anatomical Pathology business for approx. US$1.14 billion.

Apparently, the business of Anatomical Pathology will be operating as Epredia, a stand-alone company which will serve as a major provider of comprehensive solutions in the field of anatomical pathology that also includes instruments, consumables and microscope slides.

According to reports, a global healthcare company, PHC Holdings (PHCHD) offers value-added services and products across life sciences, healthcare IT and diabetes care. The acquisition will help PHCHD strengthen its business for diagnostics as it will expand its portfolio into oncology, further supporting the business growth.

President and CEO, PHCHD, Michael Kloss said that the company is looking forward to adding the leading global provider of anatomical pathology solutions to their group. Epredia will provide solutions and high quality products that deliver excellence of precision in cancer diagnostics.

Kloss mentioned that it is a highly successful business, showing a considerable growth and the company believes they can work together and make it more successful by being a part of the PHCHD group.

President of Epredia, James Post commented that the company is looking forward to joining PHCHD group. Despite bearing a new name, Epredia aims to fulfill the same mission, that is to enhance cancer diagnostics for patients and improve lives all over the world. The company has been powered by few key brands like the Menzel, Shandon, Richard Allan and Erie, and the customers have started to appreciate their precision and excellence, Post added.

Kloss further explained that the acquisition is essential for PHCHD group because the company sees a major potential for growth in the business and foresees opportunities for synergies with the existing business segment. This is an important step ahead for the group to continue to build a healthcare company that contributes to the health of the society and eventually improve lives. Kloss added.

Source Credit-  https://www.phchd.com/global/news/2019/0629



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...